CoreCap Advisors’s Skye Bioscience SKYE Stock Holding History

CoreCap Advisors’s Portfolio SKYE Stock Details SKYE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2	Hold	1	–	–	﹤0.01%	3135
2026 Q2	$6	Hold	1	–	–	﹤0.01%	3162
2026 Q1	$5	Hold	1	–	–	﹤0.01%	2925
2025 Q4	$6	Buy	+1	New	+$12	﹤0.01%	2942
2024 Q3	–	Sell	-1	Closed	-$64	–	2757
2024 Q2	$64	Buy	+1	New	+$95	﹤0.01%	1551

Other funds holding SKYE

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

SouthState Corp Winter Haven, Florida $2.48B AUM 19.33% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.1B AUM 35.17% 1-Year Est. Return

CoreCap Advisors's SKYE Position: Q3 2026 in Review

CoreCap Advisors held its Skye Bioscience (SKYE) position steady in Q3 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #3135.

CoreCap Advisors first reported a position in SKYE in Q2 2024 and has held it in 5 quarters since. The position peaked at $64 in Q2 2024. 6 funds tracked by Wall St. Rank hold SKYE as of Q3 2026.

CoreCap Advisors held 1 share of Skye Bioscience worth $2 as of Q3 2026.
CoreCap Advisors left its Skye Bioscience share count unchanged in Q3 2026.
Skye Bioscience made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #3135 holding.
CoreCap Advisors first reported a position in Skye Bioscience in Q2 2024 and has held it in 5 quarters since.
CoreCap Advisors's Skye Bioscience position peaked at $64 in Q2 2024.
6 funds tracked by Wall St. Rank held Skye Bioscience as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.